BofA/Merrill Lynch Reinstates Regeneron Pharma (REGN) at Buy
Tweet Send to a Friend
BofA/Merrill Lynch reinstates coverage on Regeneron Pharma (NASDAQ: REGN) with a Buy rating and a price target of $420.00.Analyst Ying ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE